Stat3-targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2013 Jan 25

PMID 23344460

Citations 58

Authors

Fang Liu

Juxiang Cao

Jinxiang Wu

Kayleigh Sullivan

James Shen

Byungwoo Ryu

Zhixiang Xu

Wenyi Wei

Rutao Cui

Affiliations

Soon will be listed here.

Abstract

Vemurafenib (PLX4032), a selective inhibitor of Braf, has been approved by the US Food and Drug Administration for the treatment of unresectable or metastatic melanoma in patients with Braf(V600E) mutations. Many patients treated with vemurafenib initially display dramatic improvement, with decreases in both risk of death and tumor progression. Acquired resistance, however, rapidly arises in previously sensitive cells. We attempted to overcome this resistance by targeting the signal transducer and activator of transcription 3 (STAT3)-paired box homeotic gene 3 (PAX3)-signaling pathway, which is upregulated, owing to fibroblast growth factor 2 (FGF2) secretion or increased kinase activity, with the Braf(V600E) mutation. We found that activation of Stat3 or overexpression of PAX3 induced resistance to vemurafenib in melanoma cells. In addition, PAX3 or Stat3 silencing inhibited the growth of melanoma cells with acquired resistance to vemurafenib. Furthermore, treatment with the Stat3 inhibitor, WP1066, resulted in growth inhibition in both vemurafenib-sensitive and -resistant melanoma cells. Significantly, vemurafenib stimulation induced FGF2 secretion from keratinocytes and fibroblasts, which might uncover, at least in part, the mechanisms underlying targeting Stat3-PAX3 signaling to overcome the acquired resistance to vemurafenib. Our results suggest that Stat3-targeted therapy is a new therapeutic strategy to overcome the acquired resistance to vemurafenib in the treatment of melanoma.

Citing Articles

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.

Park B, Jeon H, Kim Y, Kwon H, Choi G, Chi S Mol Cancer. 2024; 23(1):136.

PMID: 38965534 PMC: 11223307. DOI: 10.1186/s12943-024-02031-w.

Molecular network mechanism of Shexiang Huayu Xingnao granules in treating intracerebral hemorrhage.

Liu K, Bai X, Chen J, Chen G, Jamal M, He Y Ibrain. 2024; 10(2):172-185.

PMID: 38915950 PMC: 11193865. DOI: 10.1002/ibra.12131.

Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers.

Zhao K, Zhao Q, Dai X, Wen X, Luo X, Duan Y Cancer Cell Int. 2024; 24(1):191.

PMID: 38822350 PMC: 11143683. DOI: 10.1186/s12935-024-03371-9.

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.

Ozbay Kurt F, Lasser S, Arkhypov I, Utikal J, Umansky V J Clin Invest. 2023; 133(13).

PMID: 37395271 PMC: 10313369. DOI: 10.1172/JCI170762.

Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers.

Laurino S, Brancaccio M, Angrisano T, Calice G, Russi S, Mazzone P Biomedicines. 2023; 11(3).

PMID: 36979673 PMC: 10044743. DOI: 10.3390/biomedicines11030694.

References

Rodriguez M, Aladowicz E, Lanfrancone L, Goding C . Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 2008; 68(19):7872-81. DOI: 10.1158/0008-5472.CAN-08-0301. View

Imokawa G, Yada Y, Miyagishi M . Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem. 1992; 267(34):24675-80. View

Joseph E, Pratilas C, Poulikakos P, Tadi M, Wang W, Taylor B . The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010; 107(33):14903-8. PMC: 2930420. DOI: 10.1073/pnas.1008990107. View

Dai B, Meng J, Peyton M, Girard L, Bornmann W, Ji L . STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011; 71(10):3658-68. PMC: 3392199. DOI: 10.1158/0008-5472.CAN-10-3647. View

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Amin H, McDonnell T, Ma Y, Lin Q, Fujio Y, Kunisada K . Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004; 23(32):5426-34. DOI: 10.1038/sj.onc.1207703. View

Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga-Kalabis M, Cipolla A . Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18(6):683-95. PMC: 3026446. DOI: 10.1016/j.ccr.2010.11.023. View

Dankort D, Curley D, Cartlidge R, Nelson B, Karnezis A, Damsky Jr W . Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41(5):544-52. PMC: 2705918. DOI: 10.1038/ng.356. View

10.

Steingrimsson E, Copeland N, Jenkins N . Melanocyte stem cell maintenance and hair graying. Cell. 2005; 121(1):9-12. DOI: 10.1016/j.cell.2005.03.021. View

11.

Tsao H, Atkins M, Sober A . Management of cutaneous melanoma. N Engl J Med. 2004; 351(10):998-1012. DOI: 10.1056/NEJMra041245. View

12.

Dong L, Li Y, Cao J, Liu F, Pier E, Chen J . FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. Cell Death Differ. 2011; 19(4):616-22. PMC: 3307977. DOI: 10.1038/cdd.2011.132. View

13.

Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G . Paracrine stimulation of melanocytes by keratinocytes through basic fibroblast growth factor. Ann N Y Acad Sci. 1988; 548:180-90. DOI: 10.1111/j.1749-6632.1988.tb18805.x. View

14.

Hatiboglu M, Kong L, Wei J, Wang Y, McEnery K, Fuller G . The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2011; 131(1):8-17. PMC: 3319790. DOI: 10.1002/ijc.26307. View

15.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

16.

Abrahams A, Mowla S, Parker M, Goding C, Prince S . UV-mediated regulation of the anti-senescence factor Tbx2. J Biol Chem. 2007; 283(4):2223-30. DOI: 10.1074/jbc.M705651200. View

17.

Dunham W, Klein S, Rhodes L, Marcelo C . Oleic acid and linoleic acid are the major determinants of changes in keratinocyte plasma membrane viscosity. J Invest Dermatol. 1996; 107(3):332-5. DOI: 10.1111/1523-1747.ep12363174. View

18.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Kortylewski M, Jove R, Yu H . Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005; 24(2):315-27. DOI: 10.1007/s10555-005-1580-1. View